Compare Suncor Energy Inc. (SU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs TG Therapeutics Inc — how do they compare? Suncor Energy Inc. trades at $69.27 (market cap $79.39B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Suncor Energy Inc. is far larger — about 9.3× TG Therapeutics Inc's market cap, and Suncor Energy Inc. pays a 2.55% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SU | TGTX | |
|---|---|---|
Market Cap | $79.39B | $8.53B |
Sector | Energy | Health |
52-Week High | $69.73 | $59.06 |
52-Week Low | $38.17 | $26.94 |
Enterprise Value | $86.13B | $8.74B |
Dividend Yield | 2.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Suncor Energy (SU) trades at $67.89, up 0.83% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.54 and net income margin of 14.7%, supported by Q2 2026 earnings beating estimates. Recent news highlights leadership transition to Peter Zebedee as CEO in 2027 and a dividend declaration of $0.60 per share payable September 25, 2026.
Outlook remains positive due to robust cash flow and buyback increases, but risks include commodity price volatility and operational challenges from weather events. Analyst consensus is strongly bullish with 74% buy ratings, indicating confidence in sustained performance amid energy market fluctuations.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
